Peptide Dosing Ranges Reported in Research: A Protocol Framework Reference (Not a Recommendation)

Most peptide dosing content online has a structural problem. Ranges pulled from rat studies appear next to Phase III RCT data with nothing distinguishing them. 'Common protocol' figures from forums get repeated until they carry the weight of clinical guidelines. The source drops away; the number sticks around. This guide tries to do the opposite.

Every dosing range in this document is anchored to its source type. A figure from a rodent model is labeled as such. A Phase II human trial is distinguished from a Phase III approval. Anecdotal community reports are identified as anecdotal. Evidence tiers are made explicit before any numbers show up. The goal isn't to tell researchers what to do - that's outside the scope of this publication and, for most peptides covered here, outside what the evidence can actually support.

This document covers five tiers of peptides, organized by the quality and human-relevance of their dosing data: from FDA-approved compounds with Phase III RCT records down to peptides where credible published dosing data is essentially nonexistent. A regulatory disclaimer is attached to every dosing section. The three featured research peptides in this guide - GHK-Cu, Ipamorelin, and BPC-157 - all fall in the lower tiers, which is itself a meaningful finding. Understanding where a peptide sits in the evidence hierarchy is the first step toward evaluating it honestly.

How to Read This Document: Evidence Tiers, Source Labels, and Why Context Is Everything

Dosing ranges in peptide research can't be responsibly presented without their methodological context. A dose that produced a statistically significant outcome in a 12-week double-blind RCT in 200 humans is categorically different from a dose extrapolated from a rat study using allometric scaling, which is itself different from a figure that circulates in biohacker forums because it appeared in a well-written Reddit thread. All three can look identical once you strip the labels.

This document uses the following source labels throughout:

• RCT-Ph3: Randomized controlled trial, Phase III - highest evidence tier for human dosing
• RCT-Ph2: Phase II human trial data - promising but not yet approval-grade
• PK/Clinical: Published human pharmacokinetic or early clinical study, not necessarily powered for efficacy
• Animal: Rodent or other non-human animal model data
• In Vitro: Cell culture or tissue data - mechanistic insight only, no dosing relevance for in vivo use
• Anecdotal: Community self-reports, forum aggregations, practitioner case series without controls

When a dosing range has multiple source types, they're listed separately. A range supported only by animal data shouldn't be applied to humans without independent rationale - and that rationale should come from a qualified researcher, not a content website.

---

Regulatory and Legal Disclaimer: Research Contexts vs. Human Use

This entire document is published for educational and research reference purposes only. It does not constitute medical advice, a clinical protocol, or a recommendation for human use of any substance described herein.

The peptides covered in Tiers 3 through 5 of this document are not approved by the FDA, MHRA, TGA, or EMA for human therapeutic use. In most jurisdictions, they're classified as research chemicals - legal to purchase for laboratory research, but not approved for human consumption or self-administration. Legal and regulatory status varies by country and changes over time. Readers are responsible for verifying the status of any compound in their jurisdiction before acquisition or use.

For Tier 1 compounds (semaglutide, tirzepatide, tesamorelin), an approved prescription pathway exists. These should only be obtained through a licensed prescriber. Sourcing prescription compounds from research-chemical vendors is strongly discouraged and may be illegal.

Dosing figures in this document are drawn from published research and are presented for reference only. They are not recommendations, starting points, or protocols.

---

Tier 1 - FDA/Regulatory-Approved Peptides with Phase III RCT Dosing Data

Tirzepatide

Source label: RCT-Ph3

Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist approved by the FDA for type 2 diabetes (2022) and obesity (2023). Dosing data from the SURMOUNT and SURPASS trial programs are among the most robust in modern metabolic pharmacology.

Phase III trial dosing range: 2.5 mg subcutaneous weekly (starting dose), titrated at 4-week intervals to 5 mg, 10 mg, or 15 mg weekly. The 10 mg and 15 mg doses produced the most significant weight-reduction outcomes in SURMOUNT-1 (n=2,539, 72 weeks), with the 15 mg cohort showing approximately 20.9% mean body weight reduction versus placebo.

Regulatory note: Tirzepatide is a prescription drug, not a research chemical. Legitimate access is through a licensed prescriber or telehealth platform (examples include Ro, Hims/Hers, Mochi Health). Research-chemical sourcing of tirzepatide is strongly discouraged.

Semaglutide

Source label: RCT-Ph3

Semaglutide (Ozempic for T2D, Wegovy for obesity, Rybelsus oral) is a GLP-1 receptor agonist with one of the most extensive Phase III trial records in metabolic medicine. The STEP trial program (STEP 1-4) established injectable semaglutide 2.4 mg weekly as the approved weight-management dose.

Trial dosing range for weight management: initiated at 0.25 mg subcutaneous weekly for 4 weeks, titrated upward in 0.25 mg increments every 4 weeks to the 2.4 mg maintenance dose. STEP 1 (n=1,961, 68 weeks) reported approximately 14.9% mean weight reduction at the 2.4 mg dose versus 2.4% for placebo.

Regulatory note: Same prescription-only status applies as tirzepatide. Compounded semaglutide from 503B pharmacies occupied a legal gray area during shortage periods - this situation is still evolving and jurisdiction-dependent.

Tesamorelin

Source label: RCT-Ph3

Tesamorelin (Egrifta) is an FDA-approved synthetic GHRH analogue approved for HIV-associated lipodystrophy. It's the only growth hormone-axis peptide with FDA approval for a specific indication, which makes its dosing data uniquely reliable relative to the research peptides in lower tiers.

Approved dosing: 2 mg subcutaneous injection once daily. Phase III trials (RACE trials, n=412 combined) documented significant visceral adipose tissue reduction over 26 weeks at this dose. Off-label use by non-HIV patients isn't supported by equivalent evidence and falls outside the approved indication.

---

Tier 2 - Phase II Human Trial Data (Not Yet Approved or Trial-Gated)

Retatrutide

Source label: RCT-Ph2

Retatrutide is a triple agonist (GIP, GLP-1, and glucagon receptors) in Phase III trials as of 2024-2025. Phase II data published in the New England Journal of Medicine (2023, n=338, 24 weeks) reported dose-dependent weight reduction, with the 12 mg weekly cohort showing approximately 17.5% mean body weight reduction.

Phase II dosing range studied: 1 mg, 4 mg, 8 mg, or 12 mg subcutaneous weekly. The trial used a step-up titration approach consistent with other incretin-class agents.

Critical note: Retatrutide is not FDA-approved and isn't legally available through any legitimate prescriber at this time. Vendors selling retatrutide as a research chemical exist, but the compound has no established supply-chain standards outside the clinical trial context. This is a high-caution category.

---

Tier 3 - Research Peptides with Published Human Pharmacokinetic or Clinical Data

Compounds in this tier have at least some human study data - pharmacokinetic characterizations, small clinical trials, or early safety studies. That's meaningfully different from Tier 4, but the human evidence is generally insufficient to establish efficacy for the use-cases most commonly discussed in research communities. None of these are FDA-approved for the purposes researchers typically investigate them for.

MK-677 (Ibutamoren)

Source label: PK/Clinical, some small RCTs

MK-677 is an oral ghrelin mimetic and GH secretagogue - technically not a peptide, but included here because of functional overlap with this class. Small RCTs have studied doses of 10 mg, 25 mg, and 50 mg orally once daily. A 2-year RCT (n=65, elderly adults with hip fracture) used 25 mg daily. GH and IGF-1 elevations are well-documented; body composition effects in healthy adults are less well-characterized. Side effects including water retention, increased appetite, and transient insulin resistance are consistently reported across studies.

CJC-1295

Source label: PK/Clinical

A modified GHRH analogue. A pharmacokinetic study (n=11, 2006) investigated single doses of 30, 60, 120, and 300 mcg/kg subcutaneously, documenting half-life extension via DAC (Drug Affinity Complex) technology. This study characterized PK, not efficacy for performance or body composition endpoints. Most community dosing figures (100-200 mcg 2-3x weekly) are extrapolated from this PK data combined with anecdotal reports.

PT-141 (Bremelanotide)

Source label: RCT-Ph3 for one indication

PT-141 has an interesting regulatory position: bremelanotide (Vyleesi) is FDA-approved at 1.75 mg subcutaneous as-needed for hypoactive sexual desire disorder in premenopausal women. That makes it one of the few peptides in the Tier 3 space with actual Phase III data behind it. Its use for other indications (male sexual function, tanning) remains unapproved and research-grade. Approved dosing: 1.75 mg SC 45 minutes before activity, no more than once per 24 hours.

Thymosin Alpha-1 (Thymalfasin)

Source label: Clinical, approved in some jurisdictions

Thymosin Alpha-1 (Zadaxin) is approved in several countries (Italy, China, and others) for hepatitis B, hepatitis C, and as an immunomodulator. Clinical trial dosing has typically used 1.6 mg subcutaneous twice weekly. It's not FDA-approved, but it has a more substantial human clinical record than most research peptides - dozens of published trials across multiple immune conditions.

Cerebrolysin

Source label: Clinical RCTs

Cerebrolysin is a peptide mixture derived from porcine brain protein, used clinically in parts of Europe and Asia for stroke recovery and cognitive decline. Multiple small-to-medium RCTs have been published. IV dosing ranges of 10-30 mL daily for 10-20 day courses appear in the trial literature. It's not FDA-approved. Quality and standardization of research-chemical versions is a serious concern given its biological origin.

Semax and Selank

Source label: Clinical, approved in Russia

Both Semax (an ACTH 4-10 analogue) and Selank (a tuftsin analogue) are approved pharmaceuticals in Russia for specific neurological indications. Human trial data exists but is predominantly published in Russian-language journals, which limits independent review. Intranasal dosing for Semax in clinical contexts has ranged from 200-900 mcg daily. Selank nasal spray trials have used 250-500 mcg daily doses. Outside Russia and Ukraine, both are research chemicals with no regulatory standing.

Melanotan II

Source label: Small clinical studies, predominantly anecdotal

Melanotan II has been investigated in small human studies for sexual dysfunction and tanning. A 1998 study (n=10) used 0.025 mg/kg subcutaneously. It's not approved anywhere for any indication. Adverse effects documented in even small studies include significant nausea, flushing, and spontaneous erections. Multiple case reports of serious adverse events - including melanoma-related concerns with unregulated tanning use - exist in the literature. This compound warrants heightened caution.

DSIP (Delta Sleep-Inducing Peptide)

Source label: Small clinical studies, dated

DSIP was studied in small human trials in the 1980s and 1990s for sleep disorders and pain, with IV doses in the range of 25-50 mcg/kg reported. Research interest in DSIP largely stalled - few recent publications exist. Community dosing figures are extrapolated from these dated IV studies to subcutaneous administration without clear pharmacokinetic justification.

---

Tier 4 - Peptides Whose Dosing Ranges Derive Primarily from Animal Models

Critical framing for this entire tier: The dosing ranges below come from rodent studies. Allometric scaling from rodent to human is an imprecise science even for well-characterized drugs. For research peptides where bioavailability, receptor density, and clearance rates haven't been characterized in humans, these extrapolations carry substantial uncertainty. Animal studies report what worked in a specific model under specific conditions - they don't establish human doses.

*Disclaimer: All figures in this section are from animal research contexts. They are not recommendations, starting points, or protocols for human use.*

BPC-157

Score: 67/100 | Source label: Animal (primarily), Anecdotal

Best for: Researchers investigating gastrointestinal mucosal healing, tendon repair, and NO-pathway modulation in preclinical models. The anecdotal self-research community around BPC-157 is larger than for almost any other research peptide.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a sequence in human gastric juice protein. Its preclinical record is substantial - dozens of rodent studies across tendon, gut, nerve, and muscle injury models. The mechanistic breadth is real. The human evidence gap is equally real.

Dosing in animal research contexts: Rodent studies have used subcutaneous doses in the range of 10-200 mcg/kg, with 10 mcg/kg appearing frequently in tendon and gut healing models. Oral administration has also been studied in rat models at higher microgram-per-kilogram ranges. Community-extrapolated figures for human self-research typically cite 200-500 mcg daily subcutaneously or intramuscularly, but these figures don't come from published human trials - because published human trials don't exist.

Evidence note: The rodent literature is real and mechanistically interesting. That said, a disproportionate share of published BPC-157 studies originates from a single Croatian research group. Independent replication is limited. No completed human RCTs have been published as of mid-2025.

Pros in research context:

• Extensive rodent-model literature across multiple tissue types
• Consistently low side-effect profile reported in animal studies and community self-reports
• Multiple independent mechanistic pathways (NO synthase, VEGF, EGR-1) provide biological plausibility
• Relatively affordable per-cycle cost compared to many research peptides

Cons:

• No completed human RCTs - the entire therapeutic premise remains unvalidated in humans
• Heavy research group concentration limits confidence in independent replication
• Research-chemical status means no regulatory quality assurance on commercial supply
• Oral vs. injectable pharmacokinetics aren't characterized in humans, creating dose-uncertainty even for researchers

---

Ipamorelin

Score: 68/100 | Source label: Animal, limited early human PK, Anecdotal

Best for: Researchers studying selective GH secretagogue receptor agonism and pulsatile GH release dynamics. Its selectivity profile - minimal cortisol, prolactin, and ACTH co-elevation - makes it a useful research tool relative to earlier GHRPs like GHRP-6.

Ipamorelin is a pentapeptide GH secretagogue and selective GHS-R1a agonist. Its receptor pharmacology is well-characterized and consistently documented in peer-reviewed literature. That mechanistic clarity is one of its genuine research strengths.

Dosing in research contexts: Animal studies have used subcutaneous doses of approximately 200 mcg/kg in rodent models. Early human clinical research (primarily reported in pharmaceutical development contexts, not published as accessible RCTs) examined single doses in the 1-3 mcg/kg range. Community-cited figures for self-research are typically 100-300 mcg subcutaneously, 1-3 times daily - these come from extrapolation and anecdotal calibration, not human trials.

Important pharmacokinetic note: Ipamorelin has a short half-life (approximately 2 hours in animal models). Research protocols using it are typically designed around this to simulate physiological GH pulsatility, which is meaningfully different from longer-acting GH-axis compounds.

Pros in research context:

• Highly selective GHS-R1a agonism with well-characterized receptor pharmacology
• Cortisol and prolactin selectivity documented consistently across studies
• Short half-life allows pulsatile research designs
• Wider animal-model reference base than many research peptides

Cons:

• Human trial data in healthy adults for body composition or performance endpoints is essentially absent
• Requires subcutaneous injection and cold-chain storage
• WADA-prohibited status is a material risk factor for competitive athletes subject to anti-doping testing
• Frequently combined with CJC-1295 in community protocols - those combinations have no human trial evidence base

---

GHK-Cu (Copper Peptide)

Score: 72/100 | Source label: Human RCTs (topical), Animal, In Vitro

Best for: Researchers investigating skin remodeling, wound healing signaling, and gene expression modulation. The topical evidence base is genuinely among the stronger records in the research-peptide space for skin-related endpoints.

GHK-Cu is an endogenous tripeptide - glycyl-L-histidyl-L-lysine - that naturally chelates copper(II). It was first identified by Loren Pickart in 1973. Its endogenous status and decades of published literature give it a mechanistic foundation that most research peptides simply don't have.

Dosing in research contexts:

*Topical (source: small human RCTs)*: Concentrations of 0.1% to 2% in topical formulations have been used in published dermatology studies examining collagen synthesis markers, wound healing, and skin density. Multiple small RCTs (sample sizes typically 15-60 participants) have reported statistically significant improvements in skin parameters at these concentrations.

*Injectable/systemic (source: animal and in vitro only)*: Subcutaneous doses in rodent models have ranged from 1-50 mg/kg across various wound-healing and organ-protection studies. There's no published human pharmacokinetic or clinical trial data for injectable GHK-Cu at the level of an accessible peer-reviewed RCT. Community figures for injectable self-research (typically 1-2 mg daily subcutaneously) aren't anchored to human trial data.

The 4,000-gene claim - a necessary clarification: The frequently cited claim that GHK-Cu 'influences 4,000 genes' originates from a computational analysis using the Connectivity Map database (Pickart and Margolina, 2018). This is an in silico finding - it identifies correlations between GHK-Cu-induced gene expression patterns and database entries. It's mechanistically interesting, but it shouldn't be interpreted as established clinical benefit across those gene targets.

Copper chelation verification note: COAs from research-chemical vendors rarely confirm copper chelation status. The free peptide (GHK without coordinated copper) has different biological activity than the copper complex. This is a non-trivial quality-assurance gap for injectable research applications.

Pros in research context:

• Endogenous molecule with a 50-year published research record - the foundational mechanistic case isn't manufactured
• Topical dermatological evidence base includes multiple small human RCTs, which is uncommon for a research peptide
• Favorable preliminary safety profile across published trials, with no serious adverse events documented at studied doses
• Unusually broad mechanistic research footprint spanning wound healing, antioxidant signaling, and potentially angiogenic pathways

Cons:

• Injectable systemic use cases rest almost entirely on animal and in vitro data - that human evidence gap is significant
• The gene-expression claim requires careful contextualization to avoid misrepresentation
• Copper chelation verification is rarely confirmed in vendor COAs - a real quality gap
• Topical and injectable bioavailability are fundamentally different; the topical evidence doesn't transfer to injectable dose selection

---

Additional Tier 4 Compounds

TB-500 (Thymosin Beta-4 Fragment)

Source label: Animal, Anecdotal

TB-500 is a synthetic fragment of thymosin beta-4, an endogenous protein involved in actin polymerization and tissue repair. Rodent studies have demonstrated effects on wound healing, cardiac recovery, and angiogenesis. Thymosin beta-4 itself has been investigated in human trials for specific indications (venous stasis ulcers, ophthalmic applications), but TB-500 as the specific synthetic fragment has minimal published human data. Community dosing figures (typically 2-5 mg twice weekly) derive primarily from anecdotal reports and animal-to-human extrapolation.

GHK-Cu Topical vs. Injectable Summary Table

| Application Route | Evidence Source | Human Data Available? | Notes |

|---|---|---|---|

| Topical (0.1-2%) | Small human RCTs | Yes - limited | Skin remodeling endpoints |

| Injectable systemic | Animal models, in vitro | No peer-reviewed RCTs | Copper chelation often unverified in COAs |

MOTS-c

Source label: Animal, limited early human study

MOTS-c is a mitochondrial-derived peptide with proposed roles in metabolic regulation and exercise adaptation. Animal studies are preliminary. One small human study examined MOTS-c levels (endogenous measurement, not exogenous administration). Research-chemical dosing figures circulating in the community are essentially unanchored to any published human trial.

Epithalon (Epitalon)

Source label: Animal, limited Russian-language clinical reports

Epithalon is a synthetic tetrapeptide studied in Russian research contexts for telomerase activation and longevity-adjacent endpoints. Some Russian-language clinical reports exist but are difficult to independently evaluate for methodology. Western peer-reviewed evidence is sparse. Community dosing figures (5-20 mg daily for 10-20 day courses) largely trace back to these reports and anecdotal use.

---

Tier 5 - Minimal or No Credible Dosing Data in Any Published Source

Dihexa

Source label: Animal only, no published human data

Dihexa is an angiotensin IV analogue developed at Washington State University, primarily studied in rodent models of cognitive decline. Published research has characterized its pharmacology in animal contexts. There's no published human pharmacokinetic study, no human clinical trial, and no dose-response data in humans.

Community dosing figures for Dihexa are entirely speculative extrapolations from animal data. That puts it in a different category from Tier 4 compounds where at least some informal human experience has accumulated over years. For Dihexa, even the anecdotal record is thin. The absence of human PK data means basic questions - oral bioavailability, half-life, receptor occupancy at typical doses - are unanswered in humans.

This is the appropriate Tier 5 designation: not a judgment about the compound's mechanistic interest, but an honest accounting of what data actually exists for human dosing purposes.

---

Dosing Variables That Research Protocols Control For

Published research protocols don't simply report a milligram figure. The following variables are routinely controlled for in credible research designs, and their absence from community dosing discussions is part of why those figures can be misleading.

Administration Route

Route of administration affects bioavailability dramatically. BPC-157, for example, has been studied via subcutaneous, intramuscular, intraperitoneal, oral, and topical routes in animal models - and the dose required to produce a given effect differs across routes. Community protocols often mix route-specific data without acknowledging this.

Relevant route considerations:

• Subcutaneous: Most common for injectable research peptides. Absorption is slower and more sustained than IV.
• Intramuscular: Faster onset than SC for some compounds, relevant for injury-site proximity claims sometimes made for BPC-157.
• Intranasal: Relevant for Semax, Selank, and some Cerebrolysin administration - bypasses significant first-pass degradation.
• Oral: Peptides are generally degraded by gastrointestinal proteases. BPC-157 is a notable exception in rodent models, though the mechanism of oral activity isn't fully characterized.
• Topical: Skin penetration for peptides is limited by molecular weight and formulation. GHK-Cu at 0.1-2% in a properly formulated cream is different from simply applying a dissolved powder.

Body Weight Scaling

Animal study doses are almost always reported in mcg/kg or mg/kg. Converting these to flat-dose figures for humans requires allometric scaling - a process that isn't straightforward for peptides, particularly those with receptor-saturation dynamics. Many community protocols present flat doses (e.g., '250 mcg of BPC-157') without acknowledging that the source data was weight-based and the extrapolation is imprecise.

Cycling Protocols

Published rodent studies are typically acute or short-course (days to weeks). Long-term cycling protocols commonly described in the research community (e.g., 8-week on / 4-week off structures for GH secretagogues) have almost no published human trial support. These cycling structures largely derive from anecdotal experience and theoretical concern about receptor downregulation.

Titration

GLP-1 class agents (tirzepatide, semaglutide) use titration protocols in Phase III trials specifically to manage tolerability - GI side effects are significantly more prevalent at higher doses introduced abruptly. Research peptides in lower tiers rarely have titration data because the human tolerability studies simply haven't been conducted.

---

What a Research-Grade COA Should Show: Purity Thresholds, Sterility Markers, and Vendor Red Flags

A Certificate of Analysis (COA) is the primary quality-assurance document for any research chemical. For injectable peptides, a COA isn't optional - it's the minimum acceptable documentation. Here's what credible COAs include and what their absence signals.

Minimum COA Components for Injectable Research Peptides

Identity confirmation

• Mass spectrometry (LC-MS or HRMS) confirming the molecular weight matches the target sequence
• HPLC chromatogram showing the compound at the expected retention time

Purity

• HPLC purity percentage - for research-grade injectable peptides, 98%+ is the standard threshold; below 95% is a meaningful quality flag
• The purity figure should reference the area percentage of the target peak, not a crude weight-by-weight figure

Sterility and endotoxin testing

• For any compound that will be reconstituted and injected, endotoxin (LAL test) and sterility testing are critical
• Many research chemical vendors don't perform sterility testing - that's a significant gap
• Endotoxin limits: the USP standard for injectable preparations is under 5 EU/kg/hour; research peptide COAs should specify EU/mg or EU/mL figures

Specific considerations for GHK-Cu

• Standard purity testing doesn't confirm that the copper is actually chelated to the peptide
• A copper content assay (typically ICP-MS) and confirmation that the complex is intact is required to verify the compound is GHK-Cu rather than GHK + free copper
• Most vendor COAs don't include this - it's a known gap in the market

Vendor Red Flags

• COA from an in-house lab with no third-party verification
• No LC-MS data - a COA showing only HPLC without mass confirmation can't rule out a different compound at the same retention time
• Purity figures presented as ranges rather than specific measurements
• No batch number on the COA that matches the product label
• No endotoxin or sterility data for injectable-format products
• Vendor unwilling to provide the COA before purchase
• COAs dated more than 12-18 months before purchase without re-testing documentation

---

Sourcing Considerations by Peptide Class: Prescription Pathway vs. Research-Chemical Reality

Tier 1 and 2: Prescription Pathway

Semaglutide, tirzepatide, and tesamorelin have legitimate prescription pathways. Sourcing these from research-chemical vendors is strongly discouraged - product quality, sterility, and actual compound identity can't be verified without the regulatory standards that licensed pharmacies are held to. Telehealth platforms operating with licensed prescribers are the appropriate access point for these compounds.

Tier 3-5: Research Chemical Reality

For the research peptides featured in this guide - GHK-Cu, Ipamorelin, BPC-157, and others in Tiers 3-5 - no legitimate prescription pathway exists in most jurisdictions because these compounds have no approved indications. Researchers sourcing these compounds are operating in a legal gray area in most countries.

Practical sourcing criteria for research applications:

• Third-party COAs with LC-MS and HPLC purity data, batch-matched to the specific vial
• Endotoxin testing documentation for any injectable-format product
• Vendor transparency about manufacturing location and testing laboratory identity
• Age verification and ID requirements at purchase (a basic indicator of operational seriousness)
• No unsolicited medical claims on the vendor's website - vendors making therapeutic claims about unapproved compounds are operating outside their legal lane

This publication does not link to or endorse specific research-chemical vendors. The sourcing criteria above are provided for researchers evaluating vendors independently.

---

Where to Verify: PubMed Search Strings, ClinicalTrials.gov Pointers, and Primary Source Guidance

PubMed Search Strings

The following search string structures are useful starting points. They're not exhaustive and should be refined for specific research questions.

• BPC-157 human trials: `BPC-157[Title/Abstract] AND (human[MeSH] OR clinical trial[Publication Type])`
• GHK-Cu dermatology: `GHK-Cu[Title/Abstract] OR "copper peptide"[Title/Abstract] AND skin[MeSH]`
• Ipamorelin pharmacology: `ipamorelin[Title/Abstract] AND (pharmacokinetics OR "growth hormone")`
• Semaglutide weight management: `semaglutide[Title/Abstract] AND (obesity OR "weight reduction") AND randomized[Publication Type]`
• Tirzepatide Phase III: `tirzepatide[Title/Abstract] AND (SURMOUNT OR SURPASS OR randomized controlled trial[Publication Type])`

ClinicalTrials.gov

Search by compound name at clinicaltrials.gov. Key filters:

• Study Status: Select 'Completed' to find trials with results
• Study Type: 'Interventional' for actual dosing trials vs. 'Observational'
• Phase: Filtering by Phase 2 or 3 gives the most clinically relevant data

For BPC-157 specifically: as of mid-2025, searching ClinicalTrials.gov for 'BPC-157' returns no completed interventional trials with published results in healthy human subjects - that absence is itself meaningful data.

Key Journals for Peptide Research

• *Peptides* (Elsevier) - primary venue for much preclinical peptide research
• *Journal of Peptide Science*
• *Endocrinology* and *Journal of Clinical Endocrinology and Metabolism* - for GH-axis compounds
• *NEJM*, *Lancet*, *JAMA* - for Tier 1/2 approval-track compounds
• *Skin Pharmacology and Physiology* - relevant for topical GHK-Cu literature

When evaluating any published study, note the sample size, control condition, blinding status, funding source, and whether the research group has been independently replicated. For BPC-157 specifically, cross-referencing the author list against other published BPC-157 studies is a useful exercise in evaluating how independent the evidence base actually is.